I believe the two main points for us are the contracts we have with specific drugs. With the bigger items we have on the list, we negotiate price with the drug companies. Also, the generic policy we have helps us to reduce the price.
The way our drug benefit list is designed is that we don't go with a specific brand on the list. We go by molecules. We have roughly 1,000 molecules that are considered for approval. Any brand for that molecule will be there. With internal, because we have contracts, we can go and direct a specific brand. When our patients go to civilian pharmacies, we can't direct the pharmacy to only buy from one company and therefore the cost cannot be controlled.